GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Panacea Biotec Ltd

Panacea Biotec Pharma receives Rs. 4.06 Crore GST Show Cause Notice

REGULATORY ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 24 Jul 2026, 09:49 AM IST  ·  BSE ID: f8898f97-6ce0-4bbb-80d3-f3da12942002
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's subsidiary received a tax notice questioning its past tax credits, with a potential liability of ₹4.06 Crore.
🤖 AI Summary
  • Panacea Biotec Pharma Ltd. received a ₹4.06 Crore GST Show Cause Notice.
  • Notice from Assistant Commissioner, GST, Delhi, dated July 23, 2026.
  • Allegations concern excess claim of Input Tax Credit for FY 2022-23.
  • Proposed liability includes tax, interest, and penalty.
  • Company is preparing a response and does not foresee adverse impact.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Tax Liability (including interest and penalty)
₹4.06 Crore
Tax Amount
₹2.27 Crore
Interest Amount
₹1.56 Crore
Penalty Amount
₹0.23 Crore
Financial Year
2022-23
🏢 How This Affects the Company
💰
Financial Impact
A potential financial outflow of ₹4.06 Crore, comprising tax, interest, and penalty, is contingent on the resolution of the GST notice. The company is currently assessing the situation and preparing a response.
⚠️
Risk Impact
Introduces a regulatory and financial risk related to GST compliance for the subsidiary. The company has stated it does not foresee adverse operational or financial impacts, but this is subject to the outcome of the notice.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Monitor company updates on the resolution of this GST notice.
👤
Who Is Affected
All shareholders are indirectly affected by potential contingent liabilities. The notice pertains to Panacea Biotec Pharma Limited, a wholly owned subsidiary.
🔍
Management Signal
The company's proactive preparation of a response and stated lack of anticipated adverse impact signals management's intent to address the issue efficiently.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company's formal response to the GST Show Cause Notice.
Any communication from GST authorities regarding the subsidiary's response.
Updates on the resolution of the ₹4.06 Crore alleged GST liability.
MEDIUM RISK Receipt of a significant tax notice with a potential liability of ₹4.06 Crore.
💡 Investor Takeaway
Panacea Biotec Pharma received a ₹4.06 Crore GST Show Cause Notice for FY 2022-23 regarding excess Input Tax Credit claim, including tax, interest, and penalty.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Potential ₹4.06 Crore GST liability including tax, interest, and penalty for FY 2022-23.
📅 Company Track Record
Panacea Biotec has had prior interactions with tax tribunals, including a ₹9.16 Crore tax demand cancellation for AY 2020-21 and a reversal of a ₹10.23 Crore demand for AY 2016-17. The company also appealed a 4th industrial tribunal award.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the total alleged tax liability in the GST Show Cause Notice received by Panacea Biotec Pharma?
The Show Cause Notice alleges a total tax liability of ₹4.06 Crore, which includes tax, interest, and penalty.
For which financial year was the GST Show Cause Notice issued?
The Show Cause Notice pertains to the Annual Return filed for the Financial Year 2022-23.
What is the reason for the GST Show Cause Notice issued to Panacea Biotec Pharma?
The notice alleges an excess claim of Input Tax Credit (ITC) for the Financial Year 2022-23.
What are the components of the ₹4.06 Crore alleged GST liability?
The alleged liability comprises ₹2.27 Crore for tax, ₹1.56 Crore for interest, and ₹0.23 Crore for penalty.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.